<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20171007036614N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-06-27</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>effects of acupuncture and embedding in overweight patients</public_title>
      <acronym></acronym>
      <scientific_title>Evaluating the effects of acupuncture and embedding on anthropometric indices and inflammation biomarkers in overweight patients: a randomized placebo-controlled trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>150</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/64184</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Participants are randomly divided into 3 groups by the block randomization method (ABA, ACB, BAC, BCA, CAB, CBA). group A receives acupuncture, group B embedding, and group C placebo of acupuncture. A number from 1 to 6 will be assigned to each block. To achieve sample size, 50 numbers (blocks) will be generated by an online random number generator and participants will be assigned to the groups randomly, Blinding description: Patients will be randomly divided into 3 groups. Acupuncture and its placebo is similar and patients can not identify them but embedding is different. So totally blindness for patients and physician is not possible.
Outcomes will be measured by a third party who is not aware about group of participants and type of intervention.</study_design>
      <phase>3</phase>
      <hc_freetext>Obesity.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Acupuncture. To perform acupuncture, stimulation of st40, st36, st44, lv2, lv3, st25, st26, st27, ren4, ren6, ren10, ren12, sp13-15, gb26, st32, Li13 acupoints will be performed. Acupuncture with disposable steel needles of quanqi brand size 25 x 40 are selected in acupoints based on the predominant obesity syndrome, which is sp qi def and damp. The needles are inserted vertically. In the abdominal, thigh and arm, depending on the patient's body, it is inserted between 1 to 2.5 cm, and in other areas, such as between the fingers and toes, 5 to 7 mm. Due to the predominant syndrome of patients in places such as st40, st36, st25, sp15, the tonification technique is used and in other points even technique are used. The needles stay in place for about 20 minutes. Some points such as st25, ren12, ren4, 26 gb are connected to the electrode and after 20 minutes the device is turned off, the connection is disconnected and the needles are removed. The frequency of the device will be between 10-15 Hz, depending on the patient's tolerance. The electrode will be from KWD brand and the same for patients. Each participant will receive acupuncture protocol twice a week for 4 weeks and then once a week until the end of the eighth week. Intervention 2: Intervention group: Embedding. Stimulation of St24-26, Ren4, Ren6, Ren10, Ren12, Kd17 in sterile condition using absorbable sutures each 3 weeks for 3 sessions (weeks 0, 3 and 6 of study) will be performed. Intervention 3: Control group: Acupuncture placebo. For acupuncture placebo, disposable 18 x 20 needles of quanqi brand are used. Points that are not acupoints and are at least 1 cm away from the acupoints will be selected carefully. The needle penetrates the skin up to 2 mm and even less in the hand area (only a small contact) and tries not to have a manipulation process and the needle is not deeper. To electro simulate, needles are attached to the device, the device is turned on but the patient does not receive a frequency. For this group, the needles stay in the body for 20 minutes and then come out. Each participant will visit twice a week for up to 4 weeks and then once a week until the end of the eighth week.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Gathered data will be analyzed and then published.

When:
After publishing study

To whom:
Everyone (depending on the journal policies)

Conditions:
Published article will be public.

Where to obtain:
The journal that the paper is published in.

How to obtain:
Just sending Email to corresponding author.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Sadegh Adel Mehraban</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Taleqani St., Ahmadie Clinic</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1417613151</zip>
        <telephone>+98 21 8897 4535</telephone>
        <email>sadeghadel@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Amirhooman Kazemi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Taleqani St., Ahmadie clinic</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1417613151</zip>
        <telephone>+98 21 8897 4535</telephone>
        <email>amirhoomank@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age 25-65 years old
Overweight patients (BMI 25-29.9)</inclusion_criteria>
      <agemin>25 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnancy
Lactation
Any significant underlying disease (pulmonary, cardiovascular, liver, cancer, etc.)
Diet within the past 6 months</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E66</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Overweight and obesity</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Acupuncture. To perform acupuncture, stimulation of st40, st36, st44, lv2, lv3, st25, st26, st27, ren4, ren6, ren10, ren12, sp13-15, gb26, st32, Li13 acupoints will be performed. Acupuncture with disposable steel needles of quanqi brand size 25 x 40 are selected in acupoints based on the predominant obesity syndrome, which is sp qi def and damp. The needles are inserted vertically. In the abdominal, thigh and arm, depending on the patient's body, it is inserted between 1 to 2.5 cm, and in other areas, such as between the fingers and toes, 5 to 7 mm. Due to the predominant syndrome of patients in places such as st40, st36, st25, sp15, the tonification technique is used and in other points even technique are used. The needles stay in place for about 20 minutes. Some points such as st25, ren12, ren4, 26 gb are connected to the electrode and after 20 minutes the device is turned off, the connection is disconnected and the needles are removed. The frequency of the device will be between 10-15 Hz, depending on the patient's tolerance. The electrode will be from KWD brand and the same for patients. Each participant will receive acupuncture protocol twice a week for 4 weeks and then once a week until the end of the eighth week.</i_keyword>
      <i_keyword>Intervention group: Embedding. Stimulation of St24-26, Ren4, Ren6, Ren10, Ren12, Kd17 in sterile condition using absorbable sutures each 3 weeks for 3 sessions (weeks 0, 3 and 6 of study) will be performed.</i_keyword>
      <i_keyword>Control group: Acupuncture placebo. For acupuncture placebo, disposable 18 x 20 needles of quanqi brand are used. Points that are not acupoints and are at least 1 cm away from the acupoints will be selected carefully. The needle penetrates the skin up to 2 mm and even less in the hand area (only a small contact) and tries not to have a manipulation process and the needle is not deeper. To electro simulate, needles are attached to the device, the device is turned on but the patient does not receive a frequency. For this group, the needles stay in the body for 20 minutes and then come out. Each participant will visit twice a week for up to 4 weeks and then once a week until the end of the eighth week.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Weight. Timepoint: Before treatment, after 4 weeks, and after 8 weeks. Method of measurement: Digital scale.</prim_outcome>
      <prim_outcome>Body mass index. Timepoint: Before treatment, after 4 weeks, and after 8 weeks. Method of measurement: Divide weight by height squared.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>IL-6. Timepoint: Before treatment and after 8 weeks. Method of measurement: ELISA.</sec_outcome>
      <sec_outcome>IL-10. Timepoint: Before treatment and after 8 weeks. Method of measurement: ELISA.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-03-14</approval_date>
        <contact_name>Ethics committee/institute of Pharmaceuticals Sciences -Tehran University of Medical Sciences</contact_name>
        <contact_address>Enqelab St. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
